Bio Integrates brings together the innovators, investors, and industry partners shaping the future of biotechnology. As scientific breakthroughs continue to expand what is possible in healthcare, the sector must also navigate new challenges: from securing sustainable funding and building resilient supply chains to harnessing emerging technologies and developing the talent needed to translate discovery into real-world impact.
This year’s event will explore how biotech companies can thrive in an increasingly complex landscape. By convening start-ups and scale-up biotech’s, pharma, investors, regulators, service providers, and academic leaders, Bio Integrates 2026 provides a stage for open dialogue, practical insights, and new connections. Together, we will explore how to unlock the full potential of biotechnology and accelerate the journey from breakthrough science to patient impact.
Rezon Bio
Chief Executive Officer
Adriana Kiędzierska-Mencfeld is the Chief Executive Officer of Rezon Bio, where she leads the organization end-to-end, setting the strategic direction, driving operational excellence, and fostering strong client partnerships to deliver high-quality biologics development and commercial manufacturing services.
With over two decades of experience in the biotechnology industry, Adriana brings deep expertise in recombinant protein expression, purification, and biosimilar development. Prior to her current role, she held senior leadership roles at Polpharma Biologics, including Production Director, Site Head and Chief Operating Officer. There, she played a pivotal role in transitioning the company from development to commercial-scale manufacturing. Her leadership was instrumental in securing FDA and EMA approvals, executing greenfield and brownfield projects, and launching two biosimilar molecules to global markets. She has also demonstrated a strong focus on people development, fostering teams and building a culture of growth and excellence.
Earlier in her career, Adriana worked at a small Polish biotech company, contributing to both the development and the establishment of clinical production capabilities. She has a robust background in GMP production, technical operations and operational excellence, making her an industry leader in biopharmaceutical manufacturing.
Adriana holds a Ph.D. in Molecular Biology and Biotechnology from the University of Wroclaw, and an M.Sc. in Molecular Biotechnology and Biocatalysis from Wroclaw University of Science and Technology. She is currently pursuing an Executive MBA at IMD Business School in Switzerland. Fluent in Polish and English, and proficient in German, she combines technical expertise with strategic vision to drive innovation and growth in the biopharmaceutical industry.
CoSyne Therapeutics
Co-founder and Chief Executive Officer
Louwai is the CEO and co-founder of CoSyne Therapeutics – a computational biology company with a mission to push the boundaries of technology to help patients. He is a practising clinical neurology doctor, scientist, and entrepreneur. He read neuroscience and preclinical medicine and Cambridge University, before completing clinical medical school at Oxford University. He then studied entrepreneurship and revolutionary ventures at Harvard University as a Kennedy Scholar. While in Boston, he won the Massachusetts institute of Technology (MIT) $100k Accelerate entrepreneurship competition. He also founded an internationally recognised teaching platform for medical students in warzones. Louwai co-founded CoSyne Therapeutics with his team who believe in rapid translation of research into therapies to help patients.
Cyclana Bio
Founder & Chief Executive Officer
With a background in Veterinary Medicine and a PhD in Neuroscience from Cambridge University, Léa brings years of therapeutic research experience in both academia and industry. She is now applying her learnings in epigenetics and disease modelling from Altos Labs to tackling the challenges faced in Endometriosis research.
VasoDynamics
Founder & Chief Executive Officer
Specialist in Clinical Oncology, with extensive research experience in tumour biology and carcinogenesis with publications in high impact journals.
Founder of London Nanjing Life Science (China) Ltd and Suzhou NG Biomedicine Ltd and developed several biotech reagent products, disinfectant products and small molecule pharmaceutical products through prototyping, clinical trials and recently marketing.
LinkGevity
Chief Growth Officer
Rafal is a seasoned executive with a track record of delivering market expansion, revenue acceleration, and commercial transformation for private equity–backed international businesses. He is known for pairing clear strategy with disciplined execution, consistently scaling operations and unlocking growth in complex, highly regulated markets.
His career combines rare commercial and legal depth. He began at a Magic Circle law firm as a project finance and M&A lawyer, advising FTSE 100 corporates and governments on large-scale cross-border financings and infrastructure transactions, before transitioning into growth leadership roles with PE-backed companies, where he built and scaled European operations from the ground up, navigated regulatory complexity, secured strategic partnerships, and established sustainable market entry. With experience across the UK, Europe, and the United States, he brings deep expertise in global expansion, strategic deal-making, and cross-border growth.
Rafal is also the Founder and Chair of the Transatlantic Future Leaders Forum, a respected program placing emerging leaders in the U.S. Congress, reflecting his long-standing commitment to public service and leadership development.
Pioneer Group
Corporate Development Director
Pioneer Group’s purpose is to provide the environment in which ambitious life sciences and healthcare companies are more likely to be successful. We support entrepreneurs from early stage business concept onwards, helping them to test their commercial viability, raise money, launch and grow within our community.
I am part of a team of committed professionals dedicated to making this happen. In particular I am responsible for contributing significantly to the growth of Pioneer Group by leading on the recruitment of new companies to Pioneer Group’s sites and by helping the growth of existing client companies.
I started professional life at the British Consulate-General in Lyon and was appointed Commercial Consul heading up the life sciences sector for France.
I have worked in UK bio-incubators since 2005 and am chair of the UK Bioincubator Forum, representing 24 bioincubators across the UK.
From investor appeal to real-world access, patients and innovators come together to explore what “access to new therapeutics” really means. The panel highlights how early patient insights can (and should) shape strategy, design, and development to ensure breakthroughs reach the people who need them most. Join us to hear firsthand experiences and practical approaches for making innovation truly impactful
NJ Redfern Ltd
Consultant
Following 5 years’ experience working in the gene therapy arena at bluebird bio, with a focus on reimbursement and commercialisation, Nicola set up NJ Redfern Ltd in 2022 to enable her to consult, coach and collaborate with other organisations.
With a consistent focus over recent decades on rare disease & oncology/ haematology, her primary attention has been on pricing and reimbursement, service delivery and shaping the external environment. She has been in the pharmaceutical industry since 1989, and has been employed by 10 different companies.
Since her company’s inception last year she has contracted with over 12 organisations on a diverse range of projects – including supporting 2 further gene therapy companies in their launch planning in the UK. Nicola was previously an active member of the ABPI – chairing the ATMP working group during 2021, a member of their Value and Access group and supporting various government affairs/communications initiatives. She has worked closely in the last 6 years with the Cell and Gene therapy catapult in the UK. More recently Nicola has been invited to sit on the advisory board for company ATMPS, has given talks at various ATMP congresses in 2022 and 23, been interviewed by Lumanity and Haemnet, and since January 2023 sits on the ethics subgroup of the International Society of Cell and Gene therapy and is a member of ATMP engage.
Nicola is committed to and motivated by patients having a choice and being able to access transformative treatment options quickly once science and innovation reaches a point to positively impact the lives of people living with significant health challenges. Having worked at Martin House hospice in Yorkshire, sat on the board of trustees at Naomi House and Jacks Place – a Hospice for children and young adults near Winchester, UK – and through working alongside multiple patient organisations over her career, she has a strong empathy and understanding of life limiting conditions and their impact on the individual, their families and society as a whole.
She has consistently demonstrated strong leadership capabilities – with a passion for creating and shaping new diverse teams – embedding a positive culture, helping individuals develop, then leading them through defining their strategic focus and driving the initiatives through to completion.
ABPI
Director, Regulatory Policy & Early Access
Dan O’Connor is medically (Leicester) and PhD (Imperial) qualified, on the specialist register for Pharmaceutical Medicine and currently the Director Regulatory and Early Access Policy at The Association of the British Pharmaceutical Industry (ABPI). He joined the ABPI from the Medicines and Healthcare products Regulatory Agency (MHRA) in 2023 where he was Deputy Director of the Innovation Accelerator and Regulatory Science. During his time at the MHRA, he held influential positions at the European Medicine Agency’s (EMA) committees and working parties and contributed to numerous scientific and regulatory project boards. Dan has special interests and expertise in drug development, rare diseases, regulatory science, early access, health innovation and patient engagement. He is Editor-Author of the Oxford Specialist Handbook in Pharmaceutical Medicine and on the editorial board for several journals. He is co-leading the work of the UK Rare Therapies Launch Pad (RTLP). Previous roles include a Clinical Lecturer post at UCL, UCH and the Ludwig Institute for Cancer Research.
Timothy Syndrome Alliance
Chair & Founder
Sophie Muir is the founder and chair of the Timothy Syndrome Alliance (TSA), a global charity advancing progress in CACNA1C-Related Disorders. Her advocacy began after a decade-long diagnostic journey for her middle son, identified through the DDD Study and the 100,000 Genomes Project. In 2019, just 43 individuals were known worldwide; today, TSA supports over 250 families globally.
Sophie leads TSA as a strategic partner to researchers and industry, translating the lived realities of CACNA1C-Related Disorders into practical insight for clinical development. Through community-led data, consensus-informed education, and sustained global collaboration, she works to reduce fragmentation, strengthen readiness for trials and ensure that therapeutic innovation is grounded in the real needs of families.
Sagio
Founder & Lead Consultant
A lifetime of wanting to understand the way things work, lead David to a BSC Hons in Physiology & Pharmacology (Uni of Sheffield) and then an MBA (Uni of Warwick).
Following a successful 25 year career in the pharmaceutical industry where David held senior roles in training, sales and marketing in the UK and internationally, David set up his consultancy Sagio with the goal is of delivering ”eureka” moments to his clients, nlocking insights that they have not recognized before.
Sagio since 2009 has developed the skills of over 200 individuals and many teams plus creating new insights for over 130 brands. “David gave my team the winning edge” is a typical client comment. David’s meets the varied need of his clients via a network of selected affiliates who live David’s values and are committed to delivery of the same level of quality as David. Diagnosed in 2010 with Parkinson’s Disease (PD) David engaged with The Cure Parkinson’s Trust (CPT) becoming increasingly active as a patient advocate creating a sizable network. Now David is a trustee of CPT. Also, an advisor to a second PD charity Spotlight YOPD and networked at board level at Parkinson’s UK.
David sits as the patient member of the National Institute of Health Resources. Neuro degenerative Diseases Clinical Trials Committee.
Pathos
Strategic Advisor
An accomplished pharma leader with a passion for continuous learning and growth, this individual brings a wealth of experience in oncology drug development. Known for a strong work ethic, adaptability, and excellent communication skills, they thrive in collaborative environments and are dedicated to discovering and developing new therapies for cancer patients. Their commitment to personal and professional development is reflected in their proactive approach and innovative problem-solving abilities.
After a highly productive 30 year career in academic oncology he has now amassed 15 years of US pharma experience ranging from blue chip large pharma to growing a small company into a fully fledged commercially successfully entity as its first CMO. Has experience across a breadth of oncology indications and therapeutic modalities.
Now seeking opportunities to apply his expertise to emerging pharma companies.
Are investment dynamics shifting from survival to renewal? Panellists will share practical advice and personal experiences, examining how investors are supporting companies from early stage through scale-up, where capital is being deployed today, and why there is renewed optimism for building the next generation of breakthrough biotechs.
Pioneer Group
Lead Investment Director
Dr Imelda Juniarsih oversees a portfolio of 40+ healthcare companies and has led over 20 investment deals. She currently serves on five company boards, driving innovation across life sciences and medtech. With a multidisciplinary background spanning pharmaceuticals, biotechnology, manufacturing, e-commerce, and medical devices, she brings unique expertise to healthcare investments. Her academic credentials include a PhD in Biotechnology and an MSc in Intellectual Property and Business Licensing, positioning her at the strategic intersection of science, technology, and commercialisation.
Gill Jennings & Every LLP
Partner | Chemistry & Life Sciences
Ross qualified as a Chartered Patent Attorney in 2011 and became a partner in 2022. He works on a variety of inventions in the biotechnology, diagnostic and therapeutic fields including microbiome therapies and microbiology, cell and oligonucleotide therapies and antibody therapeutics.
Ross is known for his clear and accessible explanations of complex matters and has a strong track record of getting challenging biotech patents granted at the European Patent Office. He has an impressive track record with European oppositions and appeals, both defending and opposing. He works with a diverse range of clients, including UK and EU-based spin-outs and SMEs, universities, investors and multinationals. In addition, he manages European patent portfolios and oppositions on behalf of overseas clients and has significant experience performing freedom to operate and infringement analysis of European biologics and diagnostic patents, as well as due diligence activities for biotech investors.
Ross is also highly experienced in obtaining biotech supplementary protection certificates (SPCs) and foreign patent term extensions.
Prior to joining GJE, Ross worked in-house at a multinational pharmaceutical company.
Cyclana Bio
Founder & Chief Executive Officer
With a background in Veterinary Medicine and a PhD in Neuroscience from Cambridge University, Léa brings years of therapeutic research experience in both academia and industry. She is now applying her learnings in epigenetics and disease modelling from Altos Labs to tackling the challenges faced in Endometriosis research.
Outrun Therapeutics
Chief Scientific Officer
Matthew Fyfe is Chief Scientific Officer at Outrun Therapeutics. He has over 25 years’ experience in drug discovery and development, having formerly held Senior Leadership positions at Storm Therapeutics, Sitryx, TopiVert, Oryzon and Prosidion. Matthew has successfully led diverse research programs and multidisciplinary teams in various therapeutic areas, delivering clinical candidates that have reached Phase 2 or further in oncology, immunology, metabolic disease, neurology and ophthalmology. He is a Chartered Chemist, a Fellow of The Royal Society of Chemistry, an author of more than 40 peer-reviewed publications and an inventor on over 100 published patent families.
Lavender Ventures
Founding Partner
Gail is passionate about empowering women and advancing female health. She established Lavender Ventures to support this mission by investing in early-stage female health companies. She really enjoys helping businesses in this field expand their network, grow and internationalise.
Gail is also an Advisor to the NHS Femtech Accelerator and proud member of the femella Advisory Board, a membership organisation that supports young professional women in reaching their full potential. Outside of her professional endeavours, Gail is a Mum to a wonderful 10 year old boy and an ultramarathon runner.
How can organisations build trust and alignment across partners? And what collaboration models are proving most effective in managing risk and scaling for future growth? This session will examine how strategic partnerships and collaboration across the pharma and biotech supply chain are essential to building resilience, agility, and patient access.
VasoDynamics
Founder & Chief Executive Officer
Specialist in Clinical Oncology, with extensive research experience in tumour biology and carcinogenesis with publications in high impact journals.
Founder of London Nanjing Life Science (China) Ltd and Suzhou NG Biomedicine Ltd and developed several biotech reagent products, disinfectant products and small molecule pharmaceutical products through prototyping, clinical trials and recently marketing.
Centrix Pharma Solutions
Chief Executive Officer
Experienced Technical Director with extensive experience of working a in the pharmaceuticals industry.
I am expert in pharmaceutical development, manufacturing science and technology with a consistent track record of delivering high quality and robust medicines. I am experienced in Quality by Design, regulatory submissions and technology transfer.
I am an accomplished leader of technical functions and matrix teams across both Manufacturing and R&D organisations. I ensure success by setting the vision and develop strategies aligned to the organisations ambition, focusing on internal and external collaboration to deliver value.
As a leader of both line and matrix teams I have a people centric approach, setting high standards and driving delivery, whilst also creating an environment focused on personal development and continuous improvement to ensure everyone fulfils their potential.
SEDA
Chief Executive Officer
Paul is an established pharma executive with extensive global experience. Prior to joining Seda he was Vice President, Global Product Development at AstraZeneca, leading a group of over 350 scientists and engineers in the development of all products, manufacturing processes and analytical methods for the AstraZeneca small molecule portfolio.
AstraZeneca Global Product Development has centres in the UK, Sweden, US and China and a network of partnerships with colleagues all over the world and under Paul’s stewardship registered 10 global products.
At AstraZeneca Paul was accountable for the Drug Product CMC component of all Due Diligence assessments and was CMC lead on several multibillion dollar acquisitions. In addition, Paul is a visiting Professor of Pharmaceutics at the University of Manchester, UK and founder of the North West Centre for Drug Delivery (NoWCADD) at the University.
He is a proven senior manager and strategic leader in Pharmaceutical Development with experience across geographical boundaries. Passionate about the development of individual and group capabilities and the application of innovation and scientific rigour to bring new medicinal products to market.
He is recognised within the Industry and with Regulatory Agencies as a driving force in the establishment and realisation of best practice in CMC Quality by Design.
MHRA
Head of Analytical and Biological Sciences
Educated to doctorate level in the field of regenerative medicine, with a 10+ year progressive career in
advanced therapies, within academia and industry. In depth knowledge of medicines manufacturing,
including technical operations, translation, commercialisation, regulatory landscape, process
economics, quality assurance, and biomanufacturing processes including mAbs, mRNA, viral vectors,
gene therapies, and vaccines. Significant experience in project management and business
development, developing governance structures, and best-in-class collaborations between
academia and industry, with multiple and diverse stakeholders. Adept at fostering productive and
influential relationships, generating significant impact, and growing organisational revenues.
AI is enabling breakthroughs that were previously impossible. This session explores emerging collaboration models and what it takes to turn AI innovation into real scientific impact, with a focus on AI-driven biotech companies
IBM & Cell and Gene Therapy Catapult
Life Sciences Lead EMEA & Non Executive Director
Dr Nicole Mather has over 20 years’ experience in the health and life sciences industries and has worked across the commercial, public, and third sectors with a focus on cross-sector collaboration. Nicole currently leads IBM’s Health Data & AI and Life Sciences teams in the UK and Ireland, deploying technical expertise to deliver digital transformation across the sector.
Nicole is a Non-Executive Director of Cell and Gene Catapult, Non-Executive Director of the Wellcome Sanger Genome Research Ltd and sits on the Health Data Ministerial Industry Group. Nicole has also held roles as the founding Director of the Office for Life Sciences, and with NHS DigiTrials and the Health Research Authority.
Mills & Reeve
Partner and Head of Life Sciences
James heads Mills & Reeve’s multi-disciplinary life sciences practice. He supports businesses across the full product lifecycle, from start-up to commercialisation.
A key focus of his work is supporting clients on strategic contracting covering technology / IP in and out- licensing transactions, research collaborations, clinical trial agreements and long term partnering agreements. James also advises on sector regulation including pharma and medical device regulation, market access, borderline products, advertising and clinical trials.
Japeto
Chief Executive Officer
Leading Japeto, a forward-thinking and inclusive software development agency specialising in building better AI tools. We make AI useful and safe for the organisations that can’t risk getting it wrong.
We collaborate with healthcare, education, local government, and start-ups to solve problems and deliver impactful solutions.
MabGalaxy
Co-Founder
Dr Vivian Wong is Co-Founder of MabGalaxy, a Cambridge-based biotech developing next-generation therapeutic antibodies by integrating deep human immunology with AI-enabled discovery approaches. MabGalaxy combines advanced in vivo antibody generation with computational selection strategies to accelerate the development of treatments for immune-mediated diseases.
Vivian previously served as Head of Large Molecule Research UK at Sanofi Cambridge and held senior scientific leadership roles at Kymab, where she led multidisciplinary antibody discovery teams and contributed to programmes advancing into clinical development. She has extensive experience building high-performing research teams, implementing innovative discovery technologies, and translating rigorous science into preclinical assets.
With over a decade of experience in antibody discovery and immunology, Vivian is passionate about developing collaborative models that harness AI to improve the quality, efficiency, and success of biologics R&D.
CoSyne Therapeutics
Co-founder and Chief Executive Officer
Louwai is the CEO and co-founder of CoSyne Therapeutics – a computational biology company with a mission to push the boundaries of technology to help patients. He is a practising clinical neurology doctor, scientist, and entrepreneur. He read neuroscience and preclinical medicine and Cambridge University, before completing clinical medical school at Oxford University. He then studied entrepreneurship and revolutionary ventures at Harvard University as a Kennedy Scholar. While in Boston, he won the Massachusetts institute of Technology (MIT) $100k Accelerate entrepreneurship competition. He also founded an internationally recognised teaching platform for medical students in warzones. Louwai co-founded CoSyne Therapeutics with his team who believe in rapid translation of research into therapies to help patients.
Deep Mirror
Co-founder and Chief Executive Officer
Dr Max Jakobs is the CEO and co-founder of deepmirror, a University of Cambridge spin-out that helps chemists build and deploy AI models to tackle potency and ADMET challenges. He holds a PhD in Physical Biology from the University of Cambridge and has led deepmirror from 0 to $4M+ in investment and 11 employees.
Pharma is evolving rapidly, driven by accelerated innovation, emerging technologies, and
strategic regulatory and IP considerations. Panellists will discuss how companies can manage
deal flow, licensing, and partnerships while protecting long-term growth and strategic
priorities – balancing pharma interest without compromising value.
Moderna
Country Medical Director, UK
Country Medical Director at Moderna UK, Dr Philip Cruz, has over 15 years of experience in medical affairs in the field of vaccines and paediatrics within the pharmaceutical industry. At Moderna in the UK, Dr Cruz is responsible for the development and execution of the medical affairs strategy for Moderna’s infectious disease franchise and drives scientific leadership for the vaccine portfolio, while ensuring compliance with applicable policies and procedures. He also ensures effective interactions with key UK scientific leaders, public health experts, scientific and medical associations and healthcare authorities at the national level, providing country insight-gathering activities to meet the company needs around the clinical development and innovation in the field of vaccination.
Dr Cruz worked at GSK Vaccines for over 11 years, eventually assuming the role of Vaccines Medical Director for the UK and Ireland. Following his time at GSK, he was appointed as Senior Global Medical Affairs Leader (Vaccines) at AstraZeneca. He has a breadth of experience in clinical development and continues his involvement in clinical trials as a local medical lead. His role as an ABPI final signatory has given him established knowledge in medical governance and he has extensive experience in pharmaceutical medical affairs.
A paediatrician by training, Dr Cruz is actively involved in clinical research, research and development and pharmaceutical medicine.
Rezon Bio
Chief Executive Officer
Adriana Kiędzierska-Mencfeld is the Chief Executive Officer of Rezon Bio, where she leads the organization end-to-end, setting the strategic direction, driving operational excellence, and fostering strong client partnerships to deliver high-quality biologics development and commercial manufacturing services.
With over two decades of experience in the biotechnology industry, Adriana brings deep expertise in recombinant protein expression, purification, and biosimilar development. Prior to her current role, she held senior leadership roles at Polpharma Biologics, including Production Director, Site Head and Chief Operating Officer. There, she played a pivotal role in transitioning the company from development to commercial-scale manufacturing. Her leadership was instrumental in securing FDA and EMA approvals, executing greenfield and brownfield projects, and launching two biosimilar molecules to global markets. She has also demonstrated a strong focus on people development, fostering teams and building a culture of growth and excellence.
Earlier in her career, Adriana worked at a small Polish biotech company, contributing to both the development and the establishment of clinical production capabilities. She has a robust background in GMP production, technical operations and operational excellence, making her an industry leader in biopharmaceutical manufacturing.
Adriana holds a Ph.D. in Molecular Biology and Biotechnology from the University of Wroclaw, and an M.Sc. in Molecular Biotechnology and Biocatalysis from Wroclaw University of Science and Technology. She is currently pursuing an Executive MBA at IMD Business School in Switzerland. Fluent in Polish and English, and proficient in German, she combines technical expertise with strategic vision to drive innovation and growth in the biopharmaceutical industry.
LinkGevity
Chief Growth Officer
Rafal is a seasoned executive with a track record of delivering market expansion, revenue acceleration, and commercial transformation for private equity–backed international businesses. He is known for pairing clear strategy with disciplined execution, consistently scaling operations and unlocking growth in complex, highly regulated markets.
His career combines rare commercial and legal depth. He began at a Magic Circle law firm as a project finance and M&A lawyer, advising FTSE 100 corporates and governments on large-scale cross-border financings and infrastructure transactions, before transitioning into growth leadership roles with PE-backed companies, where he built and scaled European operations from the ground up, navigated regulatory complexity, secured strategic partnerships, and established sustainable market entry. With experience across the UK, Europe, and the United States, he brings deep expertise in global expansion, strategic deal-making, and cross-border growth.
Rafal is also the Founder and Chair of the Transatlantic Future Leaders Forum, a respected program placing emerging leaders in the U.S. Congress, reflecting his long-standing commitment to public service and leadership development.
Centillion Technology
Founder & Director
Harris is the founder and director of Centillion Technology Limited, based in Cambridge, UK, a biotech specialising in the rapid scaling and manufacture of RNA-based therapeutics and vaccines, He is also Professor in the Department of Engineering at King’s College London. He has a process engineering background with 28-years experience in both industry and academia. In all his past and present roles, he is managing interdisciplinary projects that require integration and coordination. Harris is an expert in continuous RNA manufacturing. His work is focusing on addressing the challenges in the rapid design, development and scalable manufacture of RNA and other nucleic acids and has pioneered the application of flow technologies in RNA manufacture, of various types. His research has attracted over £26m and he is currently leading a unique multi-disciplinary, multi-million pound programme comprising both industry and academia, building the Biofoundry-in-a-Box (BiaB). The BiaB is a unique portable, multi purpose RNA microfactory designed for the rapid design and deployment of a range of therapeutics and vaccines, with Low and Middle Income Countries in mind. He has several patents in his name in the space of RNA manufacture and continuous bioprocessing. He is highly experienced in technology transfer to industry through a variety of commercial routes.
As venture capital returns more selectively, biotech companies face heightened competition for funding. Differentiation is key – but what are investors looking for in a compelling go-to market plan? This panel will examine how founders can differentiate through technology, team, and strategy to stand out and win backing.
Mills & Reeve
Senior Legal Adviser
Isabel Teare is a senior legal adviser in Mills & Reeve’s full-service life sciences team, advising biotech, pharmaceutical, medtech and digital health clients on regulatory strategy, intellectual property and commercial matters. With a background in genetics and experience supporting fast‑growth biotech companies on regulatory and commercial issues, she brings clear, practical insight into how scientific innovation, compliance and commercial positioning shape competitiveness in the sector.
Oxford Medical Products
Chief Executive Officer
Dr Camilla Easter, has ten years biotech/mechtech start-up as CEO/COO working exclusively on hydrogel based medical devices. Originally a veterinary surgeon, she has run veterinary clinical trials and launched the veterinary arm of a biotech company. Following on from this she moved into the human biotech sector, here she was involved with all aspects of the company including, R&D, fundraising, regulatory and preclinical trials for medical devices.
DLRC
Chief Executive Officer & Founder
Dianne Lee, CEO and founder of DLRC, a global Regulatory Affairs Consultancy, leads the organisation’s strategic operations across the UK, EU, and US. Prior to DLRC’s inception in 2005, Dianne was an independent contractor for renowned pharmaceutical firms. She served as Director of Regulatory Affairs at Serono UK and contributed to Schering Plough and SK&F.
Dianne holds a BSc (Hons) in Applied Biology, is a Fellow of TOPRA, and a Fellow and Chartered Director (CDir) of the Institute of Directors, reflecting her commitment to strong governance and leadership excellence. Passionate about advancing global healthcare, she champions DLRC’s unwavering dedication to regulatory excellence while driving responsible, values‑led growth that delivers positive impact for people, patients and the planet.
Stevenage Bioscience Catalyst
Entrepreneurship and Business Development Director
As Director of Entrepreneurship and Business Development at Stevenage Bioscience Catalyst, Marco Delise provides business support to the biotech startups of the SBC cluster. He organises community-focused events, workshops and trainings, provide founders connections with industry experts and investors. He’s also responsible for directing the Catalyser accelerator programme to help startups refine their commercialisation strategy.
Previously, Marco was part of the founding team at Better Dairy, a London-based biotech startup where he led the R&D and business development streams from pre-seed to post-Series A funding stages. Marco holds a PhD in Synthetic Biology and, at SBC, he found his passion to support young biotech businesses and the broader ecosystem.
Pioneer Group
Corporate Development Director
Pioneer Group’s purpose is to provide the environment in which ambitious life sciences and healthcare companies are more likely to be successful. We support entrepreneurs from early stage business concept onwards, helping them to test their commercial viability, raise money, launch and grow within our community.
I am part of a team of committed professionals dedicated to making this happen. In particular I am responsible for contributing significantly to the growth of Pioneer Group by leading on the recruitment of new companies to Pioneer Group’s sites and by helping the growth of existing client companies.
I started professional life at the British Consulate-General in Lyon and was appointed Commercial Consul heading up the life sciences sector for France.
I have worked in UK bio-incubators since 2005 and am chair of the UK Bioincubator Forum, representing 24 bioincubators across the UK.
Victoria House, located in the heart of Bloomsbury, London, is a Grade II listed venue with state-of-the-art laboratories available for rent, designed to support scientific research and innovation. The laboratories are fully equipped with advanced technology and facilities, making them ideal for startups, established companies, and research institutions. In addition to labs, Victoria House also features flexible event spaces, advanced AV technology, and professional on-site support.
As part of the Pioneer Group, Victoria House is connected to Europe’s largest collective of scientists, technologists, and entrepreneurs. This dynamic environment supports collaboration with universities, high-growth enterprises, large corporates, healthcare providers, and local government. Pioneer Group offers a range of programmes, including Pre-Accelerator Workshops, Accelerator Programmes, and Launch support, to help businesses grow and innovate. Companies also benefit from expert networks, investment opportunities, and tailored events that foster a unique culture.
